Experience

ViiV Healthcare

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Director

  • Nov 2019 - Present

  Team leader with portfolio of projects in the early drug discovery and translational spaces. Lead immunologist providing insight across discovery and clinical programs.

• Scientific Leader and Fellow

  • Oct 2018 - Nov 2019

  Project leader for translational drug discovery programs, from target identification/validation, lead optimization, in vivo preclinical proof of concept studies and developability to clinical trials design and development strategy design.



University of North Carolina at Chapel Hill

• United States
• Higher Education
• 700 & Above Employee

• Adjunct Assistant Professor

  • Oct 2015 - Present



GSK

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Scientific Leader

  • Jul 2013 - Oct 2018

  Program leader for several HIV immunotherapy drug discovery projects. In this role I led program-specific internal biology efforts, worked with matrix partners, medicinal chemists, and pharmacologicsts to validate targets, design effective assays, perform translational proof-of-concept studies, and optimize hits into drug candidates all while participating in the design of the clinical programs to evaluate the selected molecules. I also contributed to overall group strategy and proposed new targets for validation and progression. Show less



University of California, San Francisco

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • Aug 2009 - Jul 2013

  My highly translational research aims to understand the detrimental host-pathogen interactions that foster viral persistence and pathogenesis in HIV infection. To this end, I employ comparative cross-sectional and longitudinal cohort studies and clinical trials in HIV-infected patients as well as non-human primate models of SIV infection, including non-pathogenic SIV infection of natural SIV host species. Current efforts include delineation of the driving mechanisms of chronic immune activation from the intestinal innate immune system and preclinical and clinical evaluation of novel therapeutic regimens to simultaneously intervene in chronic inflammation and viral persistence during effectively treated HIV infection. Show less



Emory University

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • Feb 2008 - Aug 2009

  Comprehensive research into the mechanisms of Hepatitis C Virus disease pathogenesis: fundamentals of hepatic adaptive immunity, novel therapeutics in non-human primate models of HCV infection, comparison of intrahepatic to peripheral T cell compartments in chronic human HCV infection.

• Graduate Student

  • Jul 2003 - Feb 2008

  Studies of Human Immunodeficiency Virus pathogenesis: characterization of perturbations of CD4+ T cell compartment in HIV-infected patients, T cell responses in SIV natural host species sooty mangabey, in-depth analysis of disease pathogenesis during pre-clinical vaccine trials.



University of Pennsylvania

• United States
• Higher Education
• 700 & Above Employee

• Visiting Scholar

  • 2006 - 2008

  Graduate Student studying HIV immunopathogenesis Graduate Student studying HIV immunopathogenesis